CMC activities for development of MAbs

Contract Pharma

Volumn , Issue 3, 2010, Pages

  Jones, Susan Dana ^a   Seymour, Patricia ^b   Levine, Howard L ^b  

^a BioProcess Technology Consultants Inc   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; MONOCLONAL ANTIBODY;

ANALYTIC METHOD; BIOENGINEERING; BIOREACTOR; CELL LINE; CHEMISTRY; CLINICAL TRIAL; COST; DRUG APPROVAL; DRUG DESIGN; DRUG FORMULATION; DRUG IMPURITY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG QUALITY; DRUG SAFETY; DRUG STABILITY; ECONOMIC DEVELOPMENT; FINANCIAL MANAGEMENT; HEALTH CARE; HUMAN; NONHUMAN; PRODUCTIVITY; QUALITY CONTROL; SCALE UP; SHORT SURVEY;

EID: 77952063094     PISSN: None     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Short Survey

References (5)

1. Ransohoff TC, et al. (BioProcess Technology Consultants Inc., Acton, MA). Cell culture manufacturing capacity: trends and outlook through 2013. Springfield (VA): Pharmsource Information Services; 2008 Dec. 126 p.
2. Ransohoff TC, Levine HL. Capacity counts. Inside Outsourcing, Pharm Exec [Internet]. 2009 Nov [cited 2009 Dec 11];29(11 Suppl):18-23. Available from: http://www.nxtbook.com/nxtbooks/advanstar/insideoutsourcing-200911/index.php? startid=18.
3. The Development of Therapeutic Monoclonal Antibody Products. Levine HL, Jagschies G, editors. Boston (MA): BioProcess Technology Consultants, Inc.; 2010 Feb. 332 p.
4. Jones SD, Technologies to Improve Cell Line Development and Engineering. Presented at Cambridge Healthtech Institute Peptalk; 2009 Jan 11-16; Coronado, CA.
5. Box GE, et al. Statistics for experimenters: design, innovation, and discovery. Second ed. Hoboken (NJ): John Wiley & Sons; c2005. 664 p.